




tumors seen clinically, constituting more than 50% of cerebral 
neoplasms in adults.[1-3]	MBT	epitomizes	the	progression	of	
a systemic malignancy (SM), and it is seen in 20%–40% of 
patients with SM.[3,4] The incidence in the United States is 
approximately 170,000/year.[3,5]
The	first	case	of	MBT	was	documented	in	1853	by	Schraut,	
and since then, there has been a perceptible increase in its 
frequency in the literature due largely to increasing availability 
and accessibility of diagnostic neuroimaging facilities and 
improvement in primary cancer survival with advancement 
in cancer therapy. Susceptibility of the brain to harboring 
metastasis has also been shown to increase with alteration 
of the blood–brain barrier by chemotherapeutic drugs, 
which permits tumor seeding into the brain and by an aging 
population.[3,4,6-9]
The	clinical	features	of	MBT	are	usually	insidious,	progressive	
and are often indistinguishable from manifestations of 
primary	 brain	 tumors	 (PBTs).[2,10] Computed tomography 
(CT) scan is the initial diagnostic tool used in excluding 
acute emergencies (hemorrhage, hydrocephalus, and 
apoplexy)	in	suspected	MBT	or	following	acute	neurological	
deterioration. Nevertheless, gadolinium-enhanced magnetic 
resonance	imaging	(GE‑MRI)	remains	the	gold	standard	for	
the	diagnosis	of	MBT.	High‑resolution	MRI	can	detect	lesions	
1–2 mm in size and reveal multiple lesions in 20% of patients 
with single lesions on contrast-enhanced CT scan. Cerebral 
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metastatic lesions are roughly spherical, well-delineated and 
often located in the arterial border zone and the gray-white 
matter interface. Metastatic brain tumours show exuberant 
peri-lesional vasogenic edema that is more profound than 
is	noticed	in	primary	brain	tumours	(PBT).	In	addition,	they	
may demonstrate a mass effect and varied patterns of contrast 
enhancement – ring, punctate, solid, or mixed patterns.[2,8,11-14]
Biopsy	remains	the	only	viable	surgical	option	for	multiple	
small deep lesions without a known primary or when the 
diagnosis of a solitary lesion is in doubt.[1,12,14] The optimal 
treatment plan will depend on patient factors (age, general 
condition,	 neurological	 status	 and	Karnofsky	Performance	




hormonal therapy, or chemotherapy) or symptomatic 
(anticonvulsants and steroids). Despite advances in cancer 
management, the multidisciplinary and multimodal approaches 
to	patients	with	MBT,	the	outcome	is	generally	poor.	Prognosis	
depends on the natural history, clinical characteristics, and 
treatment modality utilized.[2,10,14,15]
Very scanty information on this germane topic exists in 
Nigeria.	There	 is	a	changing	trend	in	MBTs	that	reflect	 the	
rapid changes in radiodiagnosis, therapeutic manipulations 
for primary disease, and neurosurgery practice in Nigeria. 
Unless	the	scope	of	the	problem	is	defined	locally,	the	expected	
surgical and palliative cares for these patients will remain 
suboptimal. This pioneering study from Southeast Nigeria 





who presented to the neurosurgery unit of the University of 
Nigeria	Teaching	Hospital,	Enugu,	Southeast	Nigeria,	 from	
December 2018 to November 2019. The hospital is government 
owned and one of the few referral centers that offer both 
neurosurgical and radiotherapy services in the country.
Consecutive patients with histologically diagnosed SM and 
radiologically	diagnosed	MBT	during	the	study	period	were	
enrolled in the study. Radiological diagnosis was made with 
cranial	GE‑MRI,	 contrast	CT,	 or	 both.	MBT	 lesions	were	
assessed	for	site,	size,	and	number	of	the	lesions.	Based	on	the	
number	of	lesions,	MBTs	were	classified	as	solitary	(only	one	
brain lesion with a controlled primary tumor in the absence 
of other metastases), single (only one brain lesion with an 
active primary tumor and other metastases outside the brain), 
or	multiple	(two	or	more	MBTs).
Patients	were	offered	 treatment	based	on	 recommendations	
of a multidisciplinary team. Surgical options were considered 
in	 patients	with	Karnofsky	Performance	Score	 (KPS)	>70,	
accessible and/or symptomatic lesions <4 in number, and 
in those with controlled SM (stable for three months or 
more). Other available treatment options include whole-brain 
radiotherapy	(WBRT)	and	chemotherapy.	Supportive	measures	
such as pain control, antiepileptic medications, and steroids 
were	also	used	as	indicated.	Patients	were	followed	up	for	one	
year	or	to	death	(whichever	comes	first).	A	structured	proforma	
was used to assess the clinical status of patients at six weeks, 
three months, six months, and 12 months post-discharge.
Data obtained were collated and analyzed using the Statistical 
Package	 for	Social	 Sciences	 version	 21,	Chicago,	 Illinois,	
USA. Descriptive and inferential statistics were derived, and 
statistical	significance	was	inferred	at	P < 0.05.
Results
Demographics and clinical profile
Of	the	31	patients	with	MBTs,	58.1%	were	female	and	41.9%	
male,	giving	a	female	to	male	ratio	of	1.4:1.	The	age	at	diagnosis	
ranged from 7 to 79 years, with a mean age of 51.0 ± 15.2 years. 
The	median	interval	from	diagnosis	of	SM	to	detection	of	MBT	
was 4.8 months (range of <1–15 months) [Table 1]. The average 
duration of cranial symptoms at presentation was 7.7 weeks.
Focal	motor	deficits	(77.8%)	and	headache	(58.1%)	were	the	
most common presenting features.
Patients’	KPSs	were	 10–40	 (45.2%),	 50–70	 (51.6%),	 and	
80–90 (25.8%).
The sources of metastases were breast (29.0%), lung (22.6%), 
skin (19.3%), and undetermined site (16.1%) [Figure 1].
Radiological characteristics
MBT	diagnosis	was	made	with	cranial	CT	scan	in	12	(38.7%)	
patients. Cranial MRI was the diagnostic modality in 14 
(45.2%) patients, while 10 patients (32.3%) performed both CT 
and MRI scans. All the solitary lesions had an MRI scan. The 
lesions were solitary in 25.8% and multiple in 74.2%. Lesions 
were predominantly located in the frontal lobes (80.6%) 
[Figure 2], with bilateral distribution in 64.5% of patients. 
The	largest	lesion	measured	8.1	cm	in	diameter.	Peri‑lesional	
edema was seen in 100% of cases, while hemorrhagic lesions 
were seen in 3 (9.7%) patients. Five patients (16.1%) had 
hydrocephalus.
Table 1: The median time interval from the diagnosis of 















Breast 9 6.6 months 3 33.3
Lungs 7 0.9 months 5 71.4
Melanoma 4 8.0 months 2 50.0
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Treatment modalities and determinants of short‑term 
outcome
WBRT	was	the	most	common	treatment	modality	for	MBT	
[Figure 3]. Of the two patients that had surgery, one had a gross 
total	resection	(GTR)	while	the	other	had	a	partial	resection.
Fifteen patients (48.4%) died within 30 days of diagnosis 
of	MBT	and	only	five	patients	(16.1%)	survived	beyond	six	
months.	Prior	knowledge	of	the	existence	of	a	SM	(P	=	0.045)	
and hemispheric involvement (P	=	0.013)	significantly	affect	
30-day survival [Table 2].
dIscussIon
Demographics and clinical profiles
MBTs	are	usually	from	Stage	4	systemic	malignancies	that	have	
spread to the brain through the hematogenous route or rarely 
by direct invasion.[8]	In	this	study,	only	31	patients	with	MBTs	
were seen. This number was short of expectations, and we 
believe	that	it	is	a	reflection	of	the	widespread	and	unfounded	
belief even among clinicians who refer these patients with 
obvious	MBT	that	“radical	or	palliative”	care	will	not	benefit	
or prolong the survival of such patients.[6]	Despite	the	figures,	
it	represents	a	significant	increase	in	diagnosis	when	compared	
to	a	previous	study	by	Adeloye	and	Odeku	who	found	17	MBT	
over three years,[6]	and	Benna	et al. who recently reported an 
average of nine patients per year over a 16-year period.[16] The 
increased	number	of	MBT	in	this	study	could	be	attributed	to	
improved cancer survival, awareness and increased access to 
neurosurgical and neurodiagnostic services in Nigeria.[17]
We found a slight female predilection among our cohorts 
accounting for 58.1% of all patients. Adeloye and Odeku 
had	previously	reported	all	patients	with	MBT	as	females.[6] 
Unlike their study which was autopsy based, this study 
was prospective. Several authors have reported a male 
preponderance	 in	MBTs.[2,16] This difference could be 
related to the frequency of primary sites. Whereas breast 
cancer predominates among our patients; lung cancers were 
more common in these other studies.[2] This is contrary to 
findings	 from	 the	Western	world	where	more	males	 than	
females	 have	MBT.	Adeloye’s	 study	 overwhelmingly	
Figure 1: Sources of metastasis to the brain
Figure 2: Distribution of lesions in the various parts of the brain
Figure 3: Treatment of metastatic brain tumor










Yes 14 (45.2) 4
No 17 (54.8) 11
Total 31 (100) 15
Karnofsky	Score
10-40 7 (22.6) 6
50-70 16 (51.6) 9
80-100 8 (25.8) 0
Total 31 (100) 15
Side of brain 0.013
Unilateral 11 (35.5) 2
Bilateral 20 (64.5) 13
Total 31 (100) 15
Number of lesions
Solitary 3 (9.7) 0
Single 5 (16.1) 1
Multiple 23 (74.2) 14
Total 31 (100) 15
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reported uterine choriocarcinoma as the most common 
source	of	SBT	(70.5%).	This	 reflects	a	changing	 trend	as	
choriocarcinomas are now readily treated with chemotherapy 
with	 better	 response	 compared	 to	 breast	 cancers.	Hence,	
breast cancers are most likely to metastasize in this era than 
choriocarcinoma.
The lungs (22.6%) and the skin (19.3%) together with the 
breast	 accounted	 for	 >70%	 of	MBTs	 [Figure 1]. This is 
comparable to other studies in the literature except that the 
lungs were unarguably the most frequent metastatic source 
in the developed countries. The relatively heavier cigarette 
smoking among Western nations compared to Nigerians has 
been proffered as a possible reason for the higher incidence 
of lung cancers in these countries.[2,12] Moreover, while the 
diagnosis of breast cancer could be more straightforward, lung 
cancers could be mimicked by infections such as pulmonary 
tuberculosis which is prevalent in our setting. These might 
explain the variation between our most common primary sites 
and that reported in other parts of the world. Of note in our 
study is that 100% of the melanoma brain metastases originated 
from cutaneous melanomas. Others have noted spread from the 
eye	or	unidentified	sites.[8,18]	In	five	of	our	patients	(16.1%),	
the	primary	site	was	not	identified.	This	is	slightly	on	the	high	
side when compared to the reported range of 2%–14%.[2,16,19] 
Out‑of‑the‑pocket	 financing	 of	 treatment	 greatly	 impedes	
proper metastasis workup in our patients.
No	case	of	incidental	finding	of	an	asymptomatic	MBT	was	
recorded in this study, unlike in developed countries, where 
more	MBTs	were	detected	before	the	occurrence	of	symptoms,	
a	reflection	of	the	disparity	in	health‑seeking	attitude	across	
both populations. Increased awareness campaigns, early 
screening, and a universal health insurance package will lead 
to	earlier	detection	of	silent	MBT.[20]
The most common presenting features among our cohorts were 
motor	 deficits	 (77.4%),	 headache	 (58.1%),	 and	 personality	




In the majority of our cases, lesions noticed on brain scan 
were mainly intraparenchymal, multiple, supratentorial, and 
frontal in location. Other locations were cerebellum (41.9%), 
leptomeningeal (9.7%), and pineal region (3.2%) [Figure 2]. 
Our	findings	corroborate	with	Stark	et al. who reported 68.0% 
lesions as supratentorial and 32.0% as infratentorial.[19] In a 
large retrospective review of 309 patients who underwent 
craniotomy for newly diagnosed brain metastases, 45.6% of 
patients had solitary brain metastasis, 26.5% had a single brain 
metastasis, and the rest had two or more brain metastases.[2] We 
observed a higher proportion of multiple lesions (74.2%) in our 
series, and this may not be unrelated to late presentation and 
limited metastasis workup early in the course of SM. Multiple 
lesions are generally accepted to be relevant in therapeutic 
considerations.[12]	Hemorrhagic	 lesions	were	 seen	 in	 three	
patients (9.7%), all of whom had melanoma, making it the 
most	 cause	 of	 hemorrhagic	MBT	 in	 our	 series.	Metastatic	
melanomas are known for hemorrhagic lesions that are 
believed to result from endothelial proliferation and necrosis, 
which predispose to bleeding with increased venous pressure 
following raised intracranial pressure.[17,20,21]
Treatment and short‑term outcome
Management	of	MBT	is	mostly	palliative.	Yet,	this	is	too	great	
a task to be left for the medical and radiation oncologist alone. 
A concerted effort is required from a multidisciplinary team 
including the clinicians (neurosurgeon, oncologist, and pain 
therapist), patients, and family members.[10] Only two patients 
(6.5%)	of	the	MBT	in	our	series	could	benefit	from	surgery,	and	
both patients survived beyond six months. These constituted 
25% of patients presenting with solitary lesions. One of the 
patients	had	a	GTR.	We	noted	that	in	selected	cases,	GTR	of	a	
single cerebral metastasis is possible because the lesions have 
well-circumscribed borders and can be delineated distinctly from 
normal surrounding brain.[11]	Hence,	when	 feasible,	 surgical	
interventions should be considered. The fewer cases of surgery 
in our study are because the patients with solitary lesions were 
fewer and had inaccessible lesions, poor performance indices, 
and uncontrolled SM. In a recent 3-year prospective study of 
cerebral metastasectomy in Ibadan, Nigeria, Ayandipo et al. 
reported better survival in 12 patients managed over the period 
compared to cohorts who had no surgery.[22]
Whole‑brain	 radiation	 therapy	 (WBRT)	was	utilized	 in	 the	
care of 18 (58.1%) of our patients [Figure 3]. In 17 patients, 
it was used as a primary modality and in one patient as an 
adjuvant.	Ten	 other	 patients	 scheduled	 for	WBRT	did	 not	
receive the treatment as they could not afford the services. 
It	 is	disheartening	that	despite	 the	key	role	WBRT	plays	in	
palliative	care	of	MBT,	it	is	not	readily	accessible	to	end‑users.	
It has been reported that even after overcoming patient-related 
factors, access to radiotherapy is hampered by equipment 
malfunctions, power outages, and workers’ strikes, among 
other reasons in Nigeria.[23] Anakwenze et al. reported that 80% 
of patients in Ibadan, Nigeria, could not afford radiotherapy 
without	financial	assistance	and	only	6%	of	the	patients	had	
federal insurance, which did not cover radiotherapy services.[24] 
It is imperative that government at all levels, corporate bodies, 
and well-meaning individuals work out funding modalities for 
cancer patients in such trying moments of their lives.
Nearly half (48.4%) died within 30 days of diagnosis, and only 
five	patients	(16.1%)	lived	beyond	six	months.	We	consider	
survival in this study as poor but not surprising, considering 
that	74.2%	of	patients	had	a	KPS	<70%,	and	only	two	patients	
were	suitable	for	any	form	of	surgical	intervention.	Benna	et al. 
reported a median survival of four months after a 33-month 
follow-up of their study.[16] Survival can be improved by 
screening and collaboration with other managing teams who 
these	patients	may	present	to	first.
The prognostic factors for a better 30-day survival were prior 
knowledge of the existence of a SM (P	=	0.045)	and	unilateral	
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brain involvement (P	=	0.013)	 [Table 2]. We postulate that 
patients who were already on treatment for SM are more likely to 
have their brain metastasis detected earlier; if the patients receive 
counseling on possible risk of metastasis, the treating clinicians 
have a lower threshold for appropriate radiological investigations, 
and the patients are likely to be referred earlier to Neurosurgery.
conclusIon
The breast is the most common SM source of brain metastasis. 
Multiple lesions were found in three-quarter of patients. Less 
than half the patients were aware of a diagnosis of malignancy 
at	the	time	of	presentation.	Survival	is	generally	poor.	Prior	
knowledge of the existence of a SM and unilateral brain 
involvement are associated with a better short-term survival. 
There is a need to entrench multidisciplinary care on cancer 
patients	to	aid	early	detection	of	MBT,	and	a	well‑structured	
multicenter study with a larger sample size is needed to 
properly arrive at practice-reshaping conclusions.
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